Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National Network (2023-12377081)
Potenziare la Gestione Clinica Delle CMF Attraverso Una Rete Nazionale Pediatrica e Dell'Adulto Basata su Dati Biologici e Genetici / Empowering the Clinical Management of BMFs Through a Biological and Genetically Driven Pediatric and Adult National Network
A non-profit, translational, prospective and retrospective study.
Patients will be enrolled according to the procedures described in the protocol, and samples will be processed and analyzed as specified in the protocol.
Since constitutional bone marrow failure syndromes (CMF) are rare genetic disorders characterized by a variable and incompletely defined clinical phenotype, a partially unknown genetic etiology, and pathogenetic mechanisms that are only partly understood, the investigators hypothesize that a number of patients currently diagnosed with idiopathic acquired aplastic anemia (AAA) or idiopathic single-lineage/multilineage bone marrow failure (BMF) may have been misdiagnosed and may actually have an underlying CMF.
Therefore, the investigators' primary objective is to identify CMF underlying BMF and vice versa, by defining well-characterized patient cohorts based on clinical and family history, clinical manifestations, and immunological findings; identifying disease-specific parameters and biomarkers; and providing disease-specific guidelines to facilitate early diagnosis and, consequently, enable timely and appropriate treatment.
In this context, the use of appropriate artificial intelligence (AI) tools is likely to improve the diagnostic accuracy of this approach.
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Carlo Dufour
- Phone Number: +3901056363528
- Email: segrematologia@gaslini.org
Study Locations
-
-
-
Avellino, Italy
- Recruiting
- AORN San Giuseppe Moscati Hematology and bone marrow Transplant Unit
-
Contact:
- Antonio Maria Risitano
- Phone Number: +393475786759
- Email: amrisita@unina.it
-
Genova, Italy
- Recruiting
- IRCCS Istituto Giannina Gaslini
-
Contact:
- Carlo Dufour
- Phone Number: +3901056363528
- Email: segrematologia@gaslini.org
-
Naples, Italy
- Recruiting
- Azienza Ospedaliera di Rilievo Nazionale Santobono Pausilipon Dipartimento di oncologia, ematologia e terapie cellulari
-
Contact:
- Giuseppe Menna
- Phone Number: +393485171510
- Email: giumenna56@libero.it
-
Verona, Italy
- Not yet recruiting
- Università degli Studi di Verona Department of Engineering for Innovation Medicine
-
Contact:
- Anna Savoia
- Phone Number: +393284695593
- Email: Anna.savoia@univr.it
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
All patients with Fanconi anemia (FA), dyskeratosis congenita (DC) and other telomere biology disorders (TBD), congenital neutropenia (CN), primary immune regulatory disorders (PIRD), congenital amegakaryocytic thrombocytopenia (CAMT), and acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)
Description
Inclusion Criteria:
- Patients diagnosed with Fanconi anemia (FA), dyskeratosis congenita (DC) and other telomere biology disorders (TBD), congenital neutropenia (CN), primary immune regulatory disorders (PIRD), congenital amegakaryocytic thrombocytopenia (CAMT), and acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH).
- Signed informed consent and/or assent obtained from the participant and/or their parents or legal guardians, as applicable.
Exclusion Criteria:
- Absence of signed informed consent and/or assent from the participant and/or their parents or legal guardians
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Fanconi anemia (FA)
Fanconi anemia (FA) |
|
Dyskeratosis congenita (DC) e altri telomere biology disorders (TBD)
Dyskeratosis congenita (DC) e altri telomere biology disorders (TBD) |
|
Congenital neutropenia (CN)
Congenital neutropenia (CN) |
|
Primary immune regulatory disorders (PIRD)
Primary immune regulatory disorders (PIRD) |
|
Congenital amegakaryocytic thrombocytopenia (CAMT)
Congenital amegakaryocytic thrombocytopenia (CAMT) |
|
Acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH)
Acquired aplastic anemia (AAA), with or without paroxysmal nocturnal hemoglobinuria (PNH) |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Early Diagnosis and Molecular Characterization of CMF and AAA
Time Frame: Within the 24-month project period
|
To improve the early diagnosis of constitutional bone marrow failure syndromes (CMF) and acquired aplastic anemia (AAA) through the integration of clinical, laboratory, immunological, and genetic data. At least 50 newly enrolled patients will be evaluated prospectively over the first 21 months, alongside approximately 200 previously referred patients analyzed retrospectively using artificial intelligence (AI). The diagnostic work-up will include the implementation of additional tests, such as telomere length assessment by flow-FISH, serum thrombopoietin measurement, and immunophenotyping by flow cytometry. Whole-genome sequencing and functional studies will be used to identify disease-causing variants, copy number variations (CNVs), and clarify variants of uncertain significance (VUS). Early and accurate diagnosis will support appropriate targeted treatment, genetic counseling, surveillance for bone marrow failure and malignancies, and identification of suitable related donors. |
Within the 24-month project period
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Bone Marrow Failure Disorders
- Genetic Diseases, Inborn
- Metabolic Diseases
- Infant, Newborn, Diseases
- Hematologic Diseases
- Skin Diseases
- Congenital Abnormalities
- Bone Marrow Diseases
- Anemia, Hemolytic
- Anemia
- Skin Diseases, Genetic
- Genetic Diseases, X-Linked
- Skin Abnormalities
- Myelodysplastic Syndromes
- DNA Repair-Deficiency Disorders
- Anemia, Hypoplastic, Congenital
- Anemia, Aplastic
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities
- Nutritional and Metabolic Diseases
- Skin and Connective Tissue Diseases
- Hemic and Lymphatic Diseases
- Congenital Bone Marrow Failure Syndromes
- Hemoglobinuria, Paroxysmal
- Fanconi Anemia
- Dyskeratosis Congenita
- Congenital amegakaryocytic thrombocytopenia
- Neutropenia, Severe Congenital, Autosomal Recessive 3
Other Study ID Numbers
Other Study ID Numbers
- PNRR-MR1-2023-12377081 (13958)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.